Saltar al contenido
Merck
  • Prognostic significance of cytoskeleton-associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 in hepatocellular carcinoma.

Prognostic significance of cytoskeleton-associated membrane protein 4 and its palmitoyl acyltransferase DHHC2 in hepatocellular carcinoma.

Cancer (2014-05-28)
Shuang-Xi Li, Gu-Sheng Tang, Dong-Xun Zhou, Yu-Fei Pan, Ye-Xiong Tan, Jian Zhang, Bo Zhang, Zhi-Wen Ding, Li-Juan Liu, Tian-Yi Jiang, He-Ping Hu, Li-Wei Dong, Hong-Yang Wang
RESUMEN

The functions of cytoskeleton-associated membrane protein 4 (CKAP4), one kind of type II transmembrane protein, are associated with the palmitoyl acyltransferase DHHC2. The objective of the current study was to investigate CKAP4/DHHC2 expression and its prognostic significance in patients with hepatocellular carcinoma (HCC). Two independent cohorts of 416 patients with HCC were enrolled. All the patients included had defined clinicopathologic and follow-up data. Using real-time polymerase chain reaction and immunohistochemical assay, CKAP4 and DHHC2 expression were evaluated. The association between CKAP4/DHHC2 expression and HCC-specific disease-free survival and overall survival was analyzed by Kaplan-Meier curves, the log-rank test, and Multivariate Cox regression analyses. The data documented that CKAP4 expression was much higher in HCC tumor tissues compared with adjacent normal tissues and its expression was significantly correlated with tumor size, intrahepatic metastases, portal venous invasion, and Barcelona Clinic Liver Cancer stage of disease in 2 cohorts of patients. On survival analysis, patients with high CKAP4 expression appeared to have a favorable overall survival and a longer disease-free survival compared with those with low expression. DHHC2 expression was also examined in tissue microarray analysis by immunohistochemistry and the results demonstrated that 87.6% of the cases had low expression of DHHC2. Kaplan-Meier analysis indicated that a high level of DHHC2 expression predicted favorable overall survival and disease-free survival rates in both the training cohort and validation set. Furthermore, the combination of CKAP4 and DHHC2 was found to have a more powerful efficiency in prognosis prediction than either one alone. To the best of our knowledge, the current study is the first to demonstrate that the expression of CKAP4 and its palmitoyl acyltransferase DHHC2 correlates with disease progression and metastasis in patients with HCC and may provide prognostic and therapeutic value.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Palmitic acid, ≥98%, FCC, FG
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Palmitic acid, analytical standard
USP
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Palmitic acid, natural, 98%, FG
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Palmitic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Anti-CKAP4 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution